title: [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia].
abstract: Waldenström's macroglobulinaemia is a rare non-Hodgkin lymphoma with bone marrow involvement and serum immunoglobulin M monoclonal protein component. The most important risk factor is immunoglobulin M monoclonal gammopathy of undetermined significance. Clinical features vary but may include anaemia, neuropathy, infections and elevated serum viscosity. Diagnosis is confirmed by flow-cytometry made on bone marrow aspirate. Not all patients require treatment at diagnosis. The main therapeutic options include alkylating agents, nucleoside analogues and rituximab used in different combination regimens.
authors: Hæmatologisk Afdeling L, Rigshospitalet, Denmark. holmeren1@yahoo.dk
authors: Morten Orebo
authors: MO
authors: Holmström
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D001856:Bone Marrow Examination; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D011379:Prognosis; D000069283:Rituximab; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab